NASHVILLE, Tenn. / Apr 07, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that it has been named on Fortune’s 2025 World’s Most Admired Companies list. HCA Healthcare is ranked first overall in its industry.
“It is an honor to be named a World’s Most Admired Company by Fortune again this year,” said Sam Hazen, CEO of HCA Healthcare. “Recognition on this list underscores our unwavering dedication to our colleagues and patients as we continue to find ways to innovate and improve lives in the communities we serve.”
To determine the annual list, Fortune collaborated with Korn Ferry, who has conducted the research for the World’s Most Admired Companies list since 1997, to analyze 650 companies across 51 industries and in 30 countries. The top-rated companies were rated by executives, directors and analysts on nine criteria: innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment, quality of products and services, and global competitiveness.
HCA Healthcare is a collaborative and innovative healthcare network made up of approximately 316,000 colleagues united by a singular mission: Above all else, we are committed to the care and improvement of human life. The Company collaborates with care teams across its hospitals and facilities to help enhance quality, improve outcomes and share best practices in the pursuit of elevating patient care.
HCA Healthcare also serves its communities during times of crisis. In response to hurricanes Helene and Milton in 2024, more than 700 colleagues were deployed to disaster areas and the Company contributed $1.5 million to community organizations to aid in hurricane relief.
This year, HCA Healthcare was also recognized on America’s Most Innovative Companies list by Fortune. The ranking is built on three pillars: product innovation, process innovation and innovation culture. Using its expansive network of care, HCA Healthcare focuses on improving patient care by empowering care teams to develop and implement innovative AI technologies and data-driven solutions. The Company’s Digital Transformation and Innovation (DT&I) department continues to build on its technology platform investments intended to help drive quality, performance and growth while seeking to bring about positive change to improve patient and care team member experience.
Additionally, 33 HCA Healthcare hospitals were named on the 2025 Fortune/Premier 100 Top Hospitals list. The annual list is based on public data that reflect measures of clinical outcomes, operational efficiency, patient experience and financial health. The HCA Healthcare hospitals included on this year’s list are:
HCA Healthcare Top Major Teaching Hospitals
HCA Healthcare Top Teaching Hospitals
HCA Healthcare Large Community Hospitals
HCA Healthcare Medium Community Hospitals
HCA Healthcare Small Community Hospitals
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its approximately 44 million annual patient encounters to advance science, improve patient care and save lives.
All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.
Last Trade: | US$335.01 |
Daily Change: | 4.01 1.21 |
Daily Volume: | 1,793,445 |
Market Cap: | US$84.860B |
February 20, 2025 February 18, 2025 October 25, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load